Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 . | AIDS Research and Therapy BioMed Central Research Safety and efficacy of a generic fixed-dose combination of stavudine lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 50 versus CD4 50 cells mm3 Weerawat Manosuthi 1 Sukanya Chimsuntorn1 Sirirat Likanonsakul1 and Somnuek Sungkanuparph2 Open Access Address 1Bamrasnaradura Infectious Diseases Institute Ministry of Public Health Nonthaburi 11000 Thailand and 2Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok 10400 Thailand Email Weerawat Manosuthi - drweerawat@ Sukanya Chimsuntorn - drskychim@ Sirirat Likanonsakul - dimvbi@ Somnuek Sungkanuparph - rasuy@ Corresponding author Published 13 March 2007 Received 21 December 2006 Accepted 13 March 2007 AIDS Research and Therapy 2007 4 6 doi l742-6405-4-6 This article is available from http content 4 1 6 2007 Manosuthi et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Antiretroviral therapy ART with a generic fixed-dose combination FDC of stavudine d4T lamivudine 3TC nevirapine NVP is widely used in developing countries. The clinical data of this FDC among very advanced HIV-infected patients is limited. Methods A retrospective cohort study was conducted among ART-naive HIV-infected patients who were initiated a generic FDC of d4T 3TC NVP between May 2004 and October 2005. Patients were categorized into 2 groups according to the baseline CD4 group A 50 cell mm3 and group B 50 cell mm3 . Results There were 204 patients with a mean SD age of years 120 in group A and 84 in group B. Median IQR CD4 cell count was 6 1 6-29 cells mm3 in group A and 139 .
